Table of Content

1. Key Insights

2. Disease Background and Overview
2.1. Introduction
2.2. Subtypes of SCA
2.2.1. SCA1
2.2.2. SCA2
2.2.3. SCA3
2.2.4. SCA6
2.2.5. SCA7
2.3. Causes and risk factors
2.4. History
2.5. Signs and Symptoms
2.6. Pathophysiology
2.7. Diagnosis
2.8. Biomarkers
2.8.1. Neuroimaging biomarkers
2.8.2. Oculomotor biomarkers
2.8.3. Biological biomarkers

3. Epidemiology and Patient Population
3.1. Key Findings
3.2. 7MM Total Patient Population of Spinocerebellar Ataxia

4. Country Wise-Epidemiology of Spinocerebellar Ataxia
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. Total Prevalent Population of Spinocerebellar Ataxia in the United States
4.1.3. Total Diagnosed Cases of Spinocerebellar Ataxia in the United States
4.1.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the United States
4.2. EU5 Countries
4.2.1. Assumptions and Rationale
4.3. Germany
4.3.1. Total Prevalent Population of Spinocerebellar Ataxia in Germany
4.3.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Germany
4.3.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the Germany
4.4. France
4.4.1. Total Prevalent Population of Spinocerebellar Ataxia in France
4.4.2. Total Diagnosed Cases of Spinocerebellar Ataxia in France
4.4.3. Type-Specific Prevalence of Spinocerebellar Ataxia in France
4.5. Italy
4.5.1. Total Prevalent Population of Spinocerebellar Ataxia in Italy
4.5.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Italy
4.5.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Italy
4.6. Spain
4.6.1. Total Prevalent Population of Spinocerebellar Ataxia in Spain
4.6.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Spain
4.6.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Spain
4.7. United Kingdom
4.7.1. Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom
4.7.2. Total Diagnosed Cases of Spinocerebellar Ataxia in the United Kingdom
4.7.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom
4.8. Japan
4.8.1. Assumptions and Rationale
4.8.2. Total Prevalent Population of Spinocerebellar Ataxia in Japan
4.8.3. Total Diagnosed Cases of Spinocerebellar Ataxia in Japan
4.8.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the Japan

5. Treatments
5.1. Potential treatments
5.2. U.S. Guidelines
5.2.1. Local Susceptibility of Host Tissue
5.3. Europe Guidelines
5.4. Management of Spinocerebellar Ataxia

6. Unmet Needs

7. Appendix
7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight



List of Figures


Figure 1: SCA subtypes overall prevalence
Figure 2: Repeat expansions that cause ataxia
Figure 3: Harding’s classification of Spinocerebellar Ataxia, detailing the classification of SCA based on symptom presentation
Figure 4: Common disease mechanisms underlying SCAs.
Figure 5: Flowchart of molecular genetic diagnosis of SCAs
Figure 6: Total Prevalent Patient Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
Figure 7: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
Figure 8: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
Figure 9:Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
Figure 10: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
Figure 11: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
Figure 12: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
Figure 13: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
Figure 14: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
Figure 15:Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
Figure 16: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
Figure 17: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
Figure 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
Figure 19: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
Figure 20: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
Figure 21:Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
Figure 22: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
Figure 23: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
Figure 24:Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
Figure 25: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
Figure 26: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
Figure 27: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)
Figure 28: Unmet Needs of Spinocerebellar ataxia

 

List of Tables


Table 1: SCA subtypes
Table 2: SCA subtypes with associated clinical signs
Table 3: Total Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
Table 4: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
Table 5: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
Table 6: Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
Table 7: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
Table 8: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
Table 9: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
Table 10: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
Table 11: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
Table 12: Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
Table 13: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
Table 14: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
Table 15: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
Table 16: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
Table 17: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
Table 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
Table 19: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
Table 20: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
Table 21: Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
Table 22: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
Table 23: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
Table 24: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)